

October 1, 2015

# NEMUS Bioscience, Inc. to Attend Upcoming Investment Conferences

COSTA MESA, CA -- (Marketwired) -- 10/01/15 -- NEMUS Bioscience Inc.(OTCQB: NMUS), a biopharmaceutical company focused on discovering, developing and commercializing cannabinoid therapeutics, announces that it has been invited to, and will attend, two investor conferences where they will present and conduct one-on-one meetings with investors in October.

## ***Aegis Capital Corp. 2015 Growth Conference (featuring Healthcare, Technology, Telecom, and Aerospace-Defense)***

Date: October 7-9, 2015

Location: The Encore at Wynn, Las Vegas, NV

Presentation: Friday, Oct. 9, 2015 at 9:30 a.m. Pacific time

Further information at <http://www.aegisconference.com>

## ***Dawson James Securities Small Cap Growth Stock Conference***

Date: October 14-15, 2015

Location: Wyndham Grand Hotel, Jupiter, FL

Presentation: Thursday, Oct. 15, 2015 at 4:00 p.m. Eastern time

Further information at <http://www.dawsonjames.com/conference>

Conference participation is by invitation only and registration is mandatory. For more information on the conferences or to schedule a one-on-one meeting with NEMUS Bioscience management, please contact the respective conference representatives.

## **ABOUT NEMUS BIOSCIENCE, INC.**

The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabis-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabis-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS's strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.

For more information, visit [www.nemusbioscience.com](http://www.nemusbioscience.com).

## **FORWARD-LOOKING STATEMENTS**

Statements in this document that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock

price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "challenge," "predictable" "will," or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make.

Contact:

Investor Relations

Mike Cole

Vice President

MZ North America

Main: 949-259-4988

Mobile: 949-444-1341

[mike.cole@mzgroup.us](mailto:mike.cole@mzgroup.us)

[www.mzgroup.us](http://www.mzgroup.us)

Source: Nemus Bioscience